Veradermics shares surge 101.09% after-hours as upsized $256.3M IPO priced above range drives investor enthusiasm for non-hormonal hair-loss treatment.

Veradermics Inc. (MANE) surged 101.09% in after-hours trading following its New York Stock Exchange debut, driven by a highly successful $256.3 million upsized IPO. The biopharmaceutical firm priced 15 million shares at $17 each—above its marketed range—and saw its stock jump 124% to $38.02 during initial trading, valuing the company at $1.3 billion. The IPO was oversubscribed, with major institutional investors like Wellington Management and Eli Lilly expressing significant interest. Veradermics, developing a non-hormonal oral therapy for pattern hair loss in late-stage trials, capitalized on strong market demand for innovative treatments in a $9 billion U.S. market. Despite reporting a $48 million net loss for the nine months ended September 30, the offering led by Jefferies and Leerink Partners highlighted robust investor confidence in its pipeline and commercialization potential. The surge reflects enthusiasm for its position in the high-growth hair-loss sector and positive reception of its FDA approval prospects.